Perpetual Ltd Boosts Stake in Gilead Sciences Amid Dividend Hike

Perpetual Ltd significantly increased its position in Gilead Sciences by 117.9% during the fourth quarter, signaling strong institutional confidence. The investor's total holdings in the biopharmaceutical giant are now valued at approximately $3.498 million following this aggressive accumulation. This move coincides with Gilead Sciences' announcement to raise its quarterly dividend to $0.82 per share, enhancing its appeal to income-focused investors. The dividend hike reflects the company's robust cash flow and commitment to returning value to its shareholders. Currently, the stock maintains a "Moderate Buy" analyst consensus, further bolstering the bullish sentiment in the market. Market observers view this institutional rebalancing as a strategic endorsement of Gilead's long-term valuation and market position.